Lataa...
Pembrolizumab
The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor lig...
Tallennettuna:
| Julkaisussa: | J Immunother Cancer |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4539882/ https://ncbi.nlm.nih.gov/pubmed/26288737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-015-0078-9 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|